Transgene SA (TNG.PA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Alessandro Riva M.D. | CEO & Chairman of the Board | 67k | -- | 1961 |
| Ms. Lucie Larguier | Chief Financial Officer | -- | -- | -- |
| Dr. Eric Quemeneur Ph.D., Pharm.D. | Executive VP & Chief Scientific Officer | -- | -- | 1965 |
| Mr. John Felitti J.D., LLM | VP, General Counsel & Corporate Secretary | -- | -- | 1970 |
| Ms. Christelle Schwoerer | Chief Human Resources Officer | -- | -- | -- |
| Dr. Maud Brandely-Talbot M.D., Ph.D. | VP of Medical Affairs & Chief Medical Officer | -- | -- | 1954 |
| Mr. James Wentworth M.B.A., Ph.D. | VP & Chief Business Officer | -- | -- | -- |
| Ms. Gaelle Stadtler | VP & Director of Human Resources | -- | -- | 1984 |
| Kaidre Bendjama | Project Leader of Personalized Cancer Vaccines | -- | -- | -- |
| Ms. Elisabetta Castelli Ph.D. | Director of Investor Relations | -- | -- | -- |
Transgene SA
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Corporate Governance
Recent Events
Recent Events Information Not Available